Cookie technology helps us bring you the best possible experience when you visit this website. Please let us know if you're happy to accept cookies. To learn more about our policy on cookies, please review our privacy policy via the link at the bottom of the page.

en:

    • {%itemName%}
        {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%itemKeyName%} {%itemBadges%} {%arrowSpan%}
      {%selfProduct%}
    • {%itemName%}
      • {%countries%}
    • {%allMenuItem%}
      • {%languages%}

      • WHAT´S NEW In AD?

      In this section you will be able to identify the new content uploaded regularly . 

      Articles

      Videos

      Infographics & Posters

      AbbViePro Logo 2023

      Our therapy areas

      Oncology
      Immunology
      Medical Information
       

      Additional info

      Privacy Notice
      Terms Of Use

       

      For Oman HCPs.

      Department of Pharmacovigilance & Drug information.

      Directorate General of pharmaceutical affairs and Drug control.

      Ministry of health, Sultanate of Oman

      Phone Nos:: 22357687 / 22357686

      Fax: 22358489

      Email: [email protected]

      Website:www.moh.gov.om

       

      This website is intended for Gulf Healthcare Professionals

      AbbVie Biopharmaceuticals GmbH.

       

      Suite 2901, U Bora Tower,Business Bay, Dubai, UAE

      PO Box:: 118052

      OFFICE : +971 4 5506100

      FAX: +971 4 5506101

      •Patient Safety is our Priority, we will remain always by your side. For Reporting Adverse events Please Contact.

      [email protected] or Hotline: 00971564135746

      JAKa-BH-00004-MC